As GLP-1 drugs like Wegovy and Ozempic gain popularity, compounded alternatives have surfaced, promising similar benefits at lower costs but lacking regulation. This trend led to health issues for some users, prompting the FDA to clarify policies. The fallout includes a bitterness between Novo Nordisk, creator of Wegovy, and the telehealth firm Hims & Hers, which recently lost its partnership with Novo. Novo accused Hims of misusing compounded drugs under the guise of personalization. Conversely, Hims' CEO defended their practices, highlighting patient choice and the pressure they faced from Novo Nordisk.
As GLP-1 drugs like Wegovy and Ozempic grow in popularity, compounded alternatives have emerged, leading to safety concerns and regulatory scrutiny.
Novo Nordisk's termination of its partnership with Hims & Hers raised questions about marketing practices and patient safety in the compounded drug arena.
Hims & Hers CEO Andrew Dudum criticized Novo Nordisk's pressure to prioritize Wegovy, asserting it undermined patient choice and clinical integrity.
While Hims & Hers faced immediate stock losses following the partnership end, its value has stabilized, showcasing market volatility after significant events.
Collection
[
|
...
]